Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling

  title={Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling},
  author={Toshinari Minamoto and Andrei V. Ougolkov and Masayoshi Mai},
  journal={Expert Review of Molecular Diagnostics},
  pages={565 - 575}
Releasing individuals from susceptibility to and anxiety about the development of cancer is an eventual goal of cancer research. This owes much to rapid progress in molecular oncology that is supported by advances in technology. Cancers of the colon and rectum, pancreas and lung that share certain clinical and molecular oncological characteristics represent timely and important target of this field. Of the genes altered in these types of cancers, the best documented is K-ras. Currently… 
β-catenin and ras oncogenes detect most human colorectal cancer
Although oncogenic activation of β-catenin and K- ras is independent in the process of clinical cancer development, combined analysis of the two major oncogenes can detect most colorectal cancers and identify a subset of patients with poorer outcomes.
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
This book chapter presents an overview of various oncotherapies in cancer, finding that several signaling pathways are found to be associated with cancer progression and survival.
Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.
Activation of c-abl in chronic myelogenous leukaemia and acute lymphoblasticLeukaemia could also be presented as an example, which provides probably the strongest evidence for the role of proto-oncogenes in human malignancy process.
Adjuvant Immunochemotherapy with Protein-Bound Polysaccharide K for Colon Cancer in Relation to Oncogenic β-Catenin Activation
In patients with diffuse nuclear accumulation-type β-catenin activation, immunochemotherapy significantly improved recurrence-free survival, cancer death survival, and overall survival rates compared with patients receiving chemotherapy alone.
Ischemia-Induced Kras Mutations in Human Colorectal Cancer Cells : Role of Microenvironmental Regulation of MSH 2 Expression
This study suggests that ischemia may not simply select for, but can actually trigger, increased mutation rate in crucial colorectal cancer oncoproteins, establishing a novel linkage between genetic instability, tumor ischemIA, and genetic tumor progression.
Correlation of γ-catenin expression with good prognosis in medulloblastomas
Medulloblastoma is a malignant cerebellar tumor of childhood and is difficult to cure due to frequent cerebrospinal fluid dissemination, and mechanisms other than gene amplification are postulated.
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts
It is suggested that increases in tumor hypoxia induced by antiangiogenic treatment may lead to K-ras mutation and consequently tumor progression, especially in susceptible individuals.
Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression.
This study suggests that ischemia may not simply select for, but can actually trigger, increased mutation rate in crucial colorectal cancer oncoproteins, and carries important implications for applying anticancer therapies involving tumor hypoxia in microsatellite instability cancers.
ROS-modulated therapeutic approaches in cancer treatment
This review highlights oxidative stress in tumors, underlying mechanisms of different relationships of ROS and cancer cells, different ROS-mediated therapeutic strategies and the emerging role of microbiota in cancer therapy.
Oxidative Stress in Cancer
Understanding the multitude and complexity of ROS-regulated pathways in cancer cells and targeted modulation of intracellular ROS levels using antioxidants or chemotherapy at different stages of tumor progression may be an effective strategy for combination therapy.


K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.
Clinical samples used for molecular diagnosis and risk assessment include stool and lavage fluid, pancreatic and duodenal juices, and sputum andlavage fluids for colorectal, pancreas and lung cancers, respectively, and they exhibited high specificity in detecting mutations.
The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis.
Insights into the molecular basis of the relatively rare inherited syndromes familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer have had profound implications for tumorigenesis in the more widespread sporadic forms of colon cancer.
Gene mutation as a target for early detection in cancer diagnosis.
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.
The present article reviews the recent advances in the diagnosis of preinvasive and early-invasive cancer to identify biomarkers for early detection of lung cancer and for chemoprevention studies.
Identification of c-MYC as a target of the APC pathway.
The c-MYC oncogene is identified as a target gene in this signaling pathway and shown to be repressed by wild-type APC and activated by beta-catenin, and these effects were mediated through Tcf-4 binding sites in the c- MYC promoter.
Blocking oncogenic Ras signaling for cancer therapy.
  • A. Adjei
  • Biology, Medicine
    Journal of the National Cancer Institute
  • 2001
The Ras gene product is a monomeric membrane-localized G protein of 21 kd that functions as a molecular switch linking receptor and nonreceptor tyrosine kinase activation to downstream cytoplasmic or
Nucleic acid-based methods for the detection of cancer.
Nucleic acid-based markers may prove to be valuable tools for early detection of cancer in asymptomatic individuals, for confirmation or exclusion of a cancer diagnosis that is based on suspicious but nondiagnostic clinical material, for assessment of tumor burden in cancer patients, and for Assessment of response to preventive approaches applied to healthy individuals who are at high risk of developing cancer.
Human cancer syndromes: clues to the origin and nature of cancer.
Though hereditary cancer syndromes are rare, their study has provided powerful insights into more common forms of cancer and will aid efforts to effectively prevent, detect, and treat the disease.
p53 Antibodies in the sera of patients with various types of cancer: a review.
  • T. Soussi
  • Medicine, Biology
    Cancer research
  • 2000
It is demonstrated that p53-Abs are found predominantly in human cancer patients with a specificity of 96%.